JPRN-UMIN000022931已完成2 期
PhaseII study of Nab-paclitaxel followed by EC as neoadjuvant chemotherapy for the operable breast cancer - PhaseII study of Nab-paclitaxel followed by EC as neoadjuvant chemotherapy for the operable breast cancer
Rakuwakai Otowa Hospital Breast oncology department0 个研究点目标入组 24 人开始时间: 2016年7月1日最近更新:
适应症
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 发起方
- 入组人数
- 24
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 20years-old 至 ot applicable（—）
- 性别
- Female
入选标准
- 未提供
排除标准
- •1) History of hypersensitivity reaction 2) Active double cander 3) Other severe complications, such as infections, diarrhea, uncontrolled angina, myocardial infarction within 6 months, heart failure. 4) Case of contraindication of this drug 5) Patients with peripheral nerve symptoms 6) Pregnant or lactating women, women who are capable of pregnancy, intend to get pregnant 7) Judged ineligible based on physicians' decision
研究者
相似试验
已完成
2 期
Phase II study of EC followed by Nab-paclitaxel as Neoadjuvant Chemotherapy for Early Breast Cancerbreast cancerJPRN-UMIN000006020Tokai University School of Medicine50
招募中
2 期
Phase II study of EC followed by Nab-paclitaxel as neoadjuvant chemotherapy for HER2 negative with lymph node metastasesbreast cancerJPRN-UMIN000010685Saitama Medical Center,Saitama Medical University40
招募中
2 期
A Phase II trial of nab-paclitaxel followed by EC as neoadjuvant chemotherapy for resectable breast cancer.breast cancerJPRN-UMIN000017382Tokyo Women's Medical University,Department of endocrine surgery36
已完成
2 期
Phase II study of Nab-paclitaxel followed by FEC as neoadjuvant chemotherapy for the operable breast cancerbreast cancerJPRN-UMIN000011048Kitasato University Kitasato Institute Hospital20
已完成
2 期
A phase 2 study of nab-Paclitaxel followed by FEC (Fluorouracil, Epirubicin, Cyclophosphamide) as primary therapy for operable breast cancerBreast CancerJPRN-UMIN000009733Hiroshima city hospital40